EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis

Abat Khan, Hira Habib, Ayesha Imran Butt, Iftikhar Khan, Khushbakhat Aziz, Ehsanullah Alokozay iD, Haneen Kamran, Soban Ali Qasim, Ammara Saleem, Shaiq Ijaz, Bilal Khan, Muhammad Siddique Karimi und 3 weitere

Systematic Reviews · 2026

DOI: 10.1186/s13643-026-03216-8 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Systematic Reviews, 2026. Verfasst von Abat Khan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Healthcare System, Penbrook Pines, Hollywood, FL, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Lymphoma, Large B-Cell, Diffuse, Antineoplastic Agents, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a therapeutic challenge, particularly for patients ineligible for stem-cell transplantation or CAR T-cell therapy. Loncastuximab tesirine, a CD19-directed antibody-drug conjugate, has demonstrated promising single-agent activity in recent studies and is approved in this setting. In this meta-analysis, we aim to assess the efficacy and safety of loncastuximab tesirine monotherapy in patients with R/R DLBCL. METHODS: A systematic review was conducted per PRISMA 2020 guidelines, searching PubMed, Embase, and Cochrane CENTRAL from inception until March 2025. Studies reporting clinical outcomes of loncastuximab tesirine monotherapy with defined efficacy and safety endpoints were included. Seven studies met the inclusion criteria, including three clinical trials and four observational cohort studies. Two reviewers independently extracted data. Pooled analyses were conducted in R (version 4.5.1) using absolute risk and random-effects modeling. Heterogeneity was assessed using the I2 statistic; publication bias was evaluated via Egger's test and funnel plots. RESULTS: The pooled overall response rate (ORR) was 47.3% (95% CI 33.5-61.3%), and the complete response (CR) rate was 22.0% (95% CI 16.7-27.7%). One-year overall survival (OS) and progression-free survival (PFS) were 48.2% (95% CI 17.8-79.3%) and 31.2% (95% CI 9.2-58.9%), respectively, with substantial heterogeneity across studies. In the clinical trial subgroup, ORR and CR were 47.3% (95% CI 33.3-61.5%) and 23.9% (95% CI 21.9-26.1%), while 1-year OS and PFS were 43.8% (95% CI 25.2-63.3%) and 28.0% (95% CI 14.6-43.8%), respectively. No publication bias was detected. Treatment-emergent adverse events (AEs) occurred in 98.7% of patients, with grade ≥ 3 events in 82.6%. Common hematologic AEs included anemia (47.7%; grade ≥ 3: 13.6%), leukopenia (16%, grade ≥ 3: 9.7%), neutropenia (32.9%; grade ≥ 3: 22.4%), and thrombocytopenia (24.3%; grade ≥ 3: 16.1%). Frequent non-hematologic AEs included fatigue (20%), fever (15.6%), vomiting (12.4%), and abdominal pain (11.4%). Other reported events included hypokalemia (25.5%), rash (20%), and peripheral edema (23.7%). CONCLUSION: This meta-analysis supports the efficacy of loncastuximab tesirine monotherapy in heavily pretreated R/R DLBCL, with an ORR of ~ 47% and manageable toxicity. These findings reinforce its role as a valuable treatment option in patients with limited alternatives and highlight the need for randomized studies to optimize patient selection and sequencing strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesLymphoma, Large B-Cell, DiffuseAntineoplastic AgentsAntibodies, Monoclonal, HumanizedHumansNeoplasm Recurrence, LocalBenzodiazepines

Substanzen

Immunoconjugatesloncastuximab tesirineAntineoplastic AgentsAntibodies, Monoclonal, HumanizedBenzodiazepines

Autor:innen und Institutionen

  • Memorial Healthcare System, Penbrook Pines, Hollywood, FL, USA.
  • Allama Iqbal Medical College, Lahore, Pakistan.
  • FMH College of Medicine and Dentistry, Lahore, Pakistan.
  • Social Security Hospital, Lahore, Pakistan.
  • Faculty of Medicine, Kandahar University, Kandahar, Afghanistan. hebibzaiehsanullah@gmail.com.
  • Multan Medical and Dental College, Multan, Pakistan.

ORCID-Profile: Ehsanullah Alokozay

Zitieren

APA

Khan, A., Habib, H., Butt, A. I., Khan, I., Aziz, K., Alokozay, E., Kamran, H., Qasim, S. A., Saleem, A., Ijaz, S., Khan, B., Karimi, M. S., Malik, S. J., Elahi, A., & Sandoval-Sus, J. (2026). Efficacy and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis. Systematic Reviews. https://doi.org/10.1186/s13643-026-03216-8

Vancouver

Khan A, Habib H, Butt AI, Khan I, Aziz K, Alokozay E, et al. Efficacy and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis. Systematic Reviews. 2026. doi:10.1186/s13643-026-03216-8

BibTeX
@article{Khan2026,
  author = {Khan, Abat and Habib, Hira and Butt, Ayesha Imran and Khan, Iftikhar and Aziz, Khushbakhat and Alokozay, Ehsanullah and Kamran, Haneen and Qasim, Soban Ali and Saleem, Ammara and Ijaz, Shaiq and Khan, Bilal and Karimi, Muhammad Siddique and Malik, Saad Javed and Elahi, Asim and Sandoval-Sus, Jose},
  title = {Efficacy and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis},
  journal = {Systematic Reviews},
  year = {2026},
  doi = {10.1186/s13643-026-03216-8}
}
Kostenlos starten →